Nasdaq ardx.

WALTHAM, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...

Nasdaq ardx. Things To Know About Nasdaq ardx.

Ardelyx, Inc. (NASDAQ:ARDX) rose 21.9% to $1.39 in pre-market trading after Citigroup raised its price target on the stock $7 to $13. Globus Maritime Limited (NASDAQ:GLBS) ...WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the …Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ...Ardelyx Inc (NASDAQ: ARDX)’s stock price has soared by 1.15 in relation to previous closing price of 4.33. Nevertheless, the company has seen a gain of 16.49% in its stock price over the last five trading days. PennyStocks reported 2023-11-17 that When it comes to finding penny stocks to buy, there are plenty of things […]13 thg 9, 2023 ... Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation.

Oct 31, 2023 · Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. Ardelyx, Inc. (NASDAQ:ARDX) BioNTech SE (NASDAQ:BNTX) Globus Medical, Inc. (NYSE:GMED) GW Pharmaceuticals plc (NASDAQ:GWPH) Medpace Holdings, Inc. (NASDAQ:MEDP) ... Qorvo (NASDAQ:QRVO) said the ...Nov 30, 2023 · According to 5 analysts, the average rating for ARDX stock is "Strong Buy." The 12-month stock price forecast is $8.7, which is an increase of 92.91% from the latest price.

Sean Pavone/iStock via Getty Images. At a Glance. Navigating through robust quarterly sales, particularly from its flagship IBS-C product Ibsrela (tenapanor), Ardelyx (NASDAQ:ARDX) continues to ...

WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations for tenapanor for hyperphosphatemia at the …NASDAQ: ARDX. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Ardelyx Inc stocks or shares into any …WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Real time Ardelyx (ARDX) stock price quote, stock graph, news & analysis.

Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...

Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor for adult patients with CKD on dialysis with hyperphosphatemia. The company will host a conference call on December 29, 2022, at 8:00 AM ET. To participate in the conference call, please call (866) 374-5140 (toll-free) or (404) 400-0571 (toll) and …

Ardelyx, Inc. (NASDAQ:ARDX) issued its earnings results on Tuesday, October, 31st. The biopharmaceutical company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.14. The biopharmaceutical company earned $56.39 million during the quarter, compared to analysts' expectations of $22.09 million.Ardelyx, Inc. (NASDAQ:ARDX) Number of Hedge Fund Holders: 16 Ardelyx, Inc. (NASDAQ:ARDX) is a biopharmaceutical company that designs and sells treatments for gastrointestinal, heart, and kidney ...WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, president and chief executive officer of Ardelyx, …Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ...22 thg 11, 2023 ... Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone · Unless you borrow money to ...Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

Sep 28, 2023 · WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ... Ardelyx Inc (NASDAQ:ARDX) trade information. Upright in the red during last session for losing -0.39%, in the last five days ARDX remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $3.86 price level, adding 6.76% to its value on the day.A total of 14 hedge funds in Insider Monkey’s database of hedge funds had stakes in Ardelyx Inc. (NASDAQ:ARDX). The most significant stake in Ardelyx Inc. (NASDAQ:ARDX) was owned by. 6.Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for …ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X: Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week, I would consider purchasing the 4usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.45. Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX ...

Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)

Dec 1, 2023 · Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. Ardelyx (NASDAQ: ARDX). $4.37. (6.8%). $0.28. Price as of November 29, 2023, 4:00 p.m. ET. Jump to: Overview. OverviewReturn vs. S&PCompany InfoNews & Analysis ...Ardelyx (NASDAQ:ARDX) is a good speculative biotech to look into. That's because it has been able to generate a good amount of sales with its drug ibsrela for the treatment of adults with ...ARDX Ardelyx Inc Stock - Share Price, Short Interest, Short Squeeze, Borrow Rates (NASDAQ) ... This section uses the official NASDAQ-supplied short interest and provides some value-added metrics, calculated daily. Short Interest is updated twice monthly on set schedule, but float and shares outstanding are on a different update schedule, so we ...WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...Sep. 7, 2023, 04:15 AM. H.C. Wainwright analyst Ed Arce initiated coverage with a Buy rating on Ardelyx ( ARDX – Research Report) today and set a price target of $9.00. The company’s shares ...Plug Power, Inc. Common Stock. $9.46 -1.29 -12.00%. Ardelyx, Inc. Common Stock (ARDX) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and ...

Jul 18, 2021 · Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ...

Ardelyx, Inc. (NASDAQ:ARDX) shares have gained about 47% year to date through August 10. Ardelyx, Inc. (NASDAQ:ARDX) recently posted Q2 results. GAAP EPS in the quarter came in at -$0.08 beating ...

18 thg 10, 2023 ... Swing traders and longer-term investors can profit from the significant volatility after approval. To those who haven't bought in, try after the ...Factors of Influence in 2019, Key Indicators and Opportunity within Cousins Properties, Versum Materials, Meritor, Ardelyx, Molecular Templates, and Talend S.A — New Research Emphasizes Economic ...Health care stocks were finishing near their Friday highs this afternoon, with the NYSE Health Care Index rising 1.0% while the Health Care Select Sector SPDR Fund (XLV) was up 0.9%.Nov 28, 2023 · Ardelyx Inc (NASDAQ:ARDX) trade information. Instantly ARDX has showed a red trend with a performance of -1.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.49 on Monday, 11/27/23 increased the stock’s daily price by 4.01%. 13 thg 9, 2023 ... Fintel reports that on September 12, 2023, HC Wainwright & Co. reiterated coverage of Ardelyx (NASDAQ:ARDX) with a Buy recommendation.On this news, the Company’s stock price fell $0.70, or 13.4%, to close at $4.51 per share on May 26, 2021, on unusually heavy trading volume.Find the latest dividend history for Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com. Ardelyx, Inc. Common Stock (ARDX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has …Ardelyx (NASDAQ:ARDX) is a great speculative biotech play to look into. Why is that? That's because despite its potential with two drugs in the pipeline, the stock is still trading with a very low ...

Health care stocks were finishing near their Friday highs this afternoon, with the NYSE Health Care Index rising 1.0% while the Health Care Select Sector SPDR Fund (XLV) was up 0.9%.Citigroup Inc. decreased its position in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the ...Ardelyx (NASDAQ:ARDX) delivers shareholders splendid 109% return over 1 year, surging 15% in the last week alone Instagram:https://instagram. block chain companiesaep stocksbest 401k investmentsaverage mortgage rates mn WALTHAM, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ... icct nasdaqdividend history mo The chain sheet shows the price, volume and open interest for each option strike price and expiration month. Nasdaq provides call and put options information of stocks. Financial analysts and ... automated share trading Ardelyx, Inc. Common Stock (ARDX) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ARDX Edit my quotes Ardelyx, Inc. Common Stock (ARDX) 0 Add to Watchlist Add to Portfolio Quotes...The FDA approved Ardelyx Inc's (NASDAQ:ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD ...Aug 28, 2023 · Ardelyx, Inc. (NASDAQ:ARDX) focuses on treatments for gastrointestinal system and kidney diseases. Its latest analyst share coverage came from Cantor Fitzgerald which upgraded the share rating to ...